SV

Street Verdict

Analyst Scorecard

A record of what Sandip Sabharwal said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on the pharma sector, noting its strong performance over recent quarters with major companies like Cipla, Lupin, Sun Pharma, and Divi's outperforming expectations. The outperformance could continue if potential reciprocal tariffs from President Trump, expected to be announced on Thursday, are not significant.”
Nifty PharmaBullishCalled 14 Feb 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Sandip Sabharwal’s full track record